THE TOXICITY OF CHEMICALLY DEGLYCOSYLATED RICIN A-CHAIN IN MICE

被引:30
|
作者
SOLERRODRIGUEZ, AM
UHR, JW
RICHARDSON, J
VITETTA, ES
机构
[1] UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235
[2] UNIV TEXAS,DEPT PATHOL,DIV COMPARAT MED,DALLAS,TX 75235
[3] UNIV TEXAS,CTR CANC IMMUNOBIOL,DALLAS,TX 75235
来源
关键词
D O I
10.1016/0192-0561(92)90041-I
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tumor-reactive antibodies coupled to ricin or its A-chain (immunotoxins) have been used in rodents and humans to treat a variety of neoplastic diseases. Side-effects of such treatment include hepatotoxicity, vascular leak syndrome, myalgia and low grade fever. At high doses, severe toxicities include liver damage, pulmonary edema, aphasia, rhabdomyolysis and kidney failure. There have been a limited number of toxicologic studies on uncoupled ricin or its A-chain and none on deglycosylated A-chain. Since the latter has been utilized in "second generation" immunotoxins, the current studies were carried out to evaluate the toxicities induced by deglycosylated ricin A-chain (dgA) in mice. The administration of dgA to normal BALB/c mice causes early (24 h) weight loss and late (10 day) accumulation of ascites. These effects could be partially altered by changing the route of injection of dgA from i.v. to i.p. Thus, i.p. administration caused weight loss but not ascites, whereas i.v. administration caused both. Weight loss was associated with reduced fluid intake by the treated mice, and was not associated with increased levels of serum TNF-alpha. SCID mice injected with the same dose of dgA as normal BALB/c mice developed ascites, but it was of lesser severity, suggesting that a functional immune system, differences in microbial flora, or strain differences may be involved in the development of ascites.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 50 条
  • [21] FLUORESCENCE STUDIES ON THE INTERACTION OF ADENINE WITH RICIN A-CHAIN
    WATANABE, K
    HONJO, E
    TSUKAMOTO, T
    FUNATSU, G
    FEBS LETTERS, 1992, 304 (2-3) : 249 - 251
  • [22] STRUCTURE OF RECOMBINANT RICIN A-CHAIN AT 2.3 ANGSTROM
    MLSNA, D
    MONZINGO, AF
    KATZIN, BJ
    ERNST, S
    ROBERTUS, JD
    PROTEIN SCIENCE, 1993, 2 (03) : 429 - 435
  • [23] PREPARATION AND APPLICATION OF ANTIBODIES COUPLED TO THE A-CHAIN OF RICIN
    KROLICK, KA
    UHR, JW
    VITETTA, ES
    METHODS IN ENZYMOLOGY, 1983, 93 : 333 - 338
  • [24] Detecting Ricin: Sensitive Luminescent Assay for Ricin A-Chain Ribosome Depurination Kinetics
    Sturm, Matthew B.
    Schramm, Vern L.
    ANALYTICAL CHEMISTRY, 2009, 81 (08) : 2847 - 2853
  • [25] A clinical phase I trial of an anti-CD25-deglycosylated ricin A-chain immunotoxin in patients with refractory Hodgkin's disease
    Schnell, R
    Hatwig, MT
    Radszuhn, A
    Cebe, F
    Drillich, S
    Schon, G
    Bohlen, H
    Tesch, H
    Hansmann, ML
    Schindler, J
    Ghetie, Y
    Uhr, J
    Diehl, Y
    Vitetta, ES
    Engert, A
    BLOOD, 1995, 86 (10) : 208 - 208
  • [26] Immunotoxins containing A-chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain
    Tonevitsky, AG
    Agapov, II
    Shamshiev, AT
    Temyakov, DE
    Pohl, P
    Kirpichnikov, MP
    FEBS LETTERS, 1996, 392 (02): : 166 - 168
  • [28] SUCCESSFUL TREATMENT OF HUMAN ACUTE T-CELL LEUKEMIA IN SCID MICE USING THE ANTI-CD7-DEGLYCOSYLATED RICIN A-CHAIN IMMUNOTOXIN DA7
    JANSEN, B
    VALLERA, DA
    JASZCZ, WB
    NGUYEN, D
    KERSEY, JH
    CANCER RESEARCH, 1992, 52 (05) : 1314 - 1321
  • [29] UPTAKE OF NATIVE DEGLYCOSYLATED RICIN A-CHAIN IMMUNOTOXINS BY MOUSE-LIVER PARENCHYMAL AND NON-PARENCHYMAL CELLS-INVITRO AND INVIVO
    BLAKEY, DC
    SKILLETER, DN
    PRICE, RJ
    THORPE, PE
    BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 968 (02) : 172 - 178
  • [30] Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant
    Kende, M
    Del Giudice, G
    Rivera, N
    Hewetson, J
    VACCINE, 2006, 24 (12) : 2213 - 2221